ForeCYTE Delivers Blow in the War Against Breast Cancer
Clarity ForeCYTE breast health test that increases early detection of precancerous breast conditions introduced at Pri-Med South Annual Conference.
Boca Raton, FL (PRWEB) February 09, 2013
The big news in the war on breast cancer is Clarity ForeCYTE Breast Health Test that was officially introduced today (February 8) at the Broward County Convention Center in South Florida and promises to deliver a severe blow to female breast cancer.
Clarity Women’s Health (a division of Diagnostic Test Group, LLC) of Boca Raton, Florida and Atossa Genetics, the Breast Health Company, based in Seattle, Washington, successfully introduced the revolutionary product at the Pri-Med South Annual Expo. The well-received, product introduction heralds a new dawn in medical science, a revolutionary breakthrough in the fight against breast cancer.
According to Pri-Med conference attendee, Sarah Glantz, “I´m very interested in ForeCYTE as it will be very beneficial and a lot easier than doing a mammogram. Glantz sentiments were expressed by fellow participant and H Lee Moffitt Cancer Center employee, Carla Moodie who expressed, “It is a great product and I think anything that deals with early detection is good. In addition, it will be done in a doctor´s office”.
Using the patented, FDA-cleared Mammary Aspirate Specimen Cytology Test (MASCT) System, a nurse or physician´s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 15 minutes. The MASCT device is intended for use in the collection of nipple aspirate fluid for cytological testing. The collected fluid can be used in the determination and/or differentiation of normal versus premalignant versus malignant cells.
CEO of Clarity Women´s Health, Rick Simpson explained, “The response from medical practitioners attending the conference has been phenomenal. The Clarity Women´s Health staff has been able to introduce the test to women of all ages and even breast cancer survivors. The value of the test was demonstrated today at the Pri-Med Expo. Based on the response of the medical community, we are excited to save lives with the ForeCYTE breast health test”.
Simpson further stated, “Clarity Women´s Health and Atossa Genetics are proud to be able to present a product that will support physicians in the care of their female patients. This product advancement in breast health will help doctors save women´s lives and help us look forward to a future where we will be fearless about breast cancer”.
ForeCYTE is targeted for over 110 million women between the ages of 18 and 73 in the U.S. who can now obtain a simple test in their physician’s office and learn their future risk of breast cancer up to eight years before mammography can pick it up. This kind of advanced information was created for cervical cancer by the Pap smear and was responsible for the 75% reduction in the incidence of cervical cancer. The ForeCYTE Breast Health Test has the potential to do the same for breast cancer.
About Clarity Women’s Health
Clarity Women’s Health is a division of Diagnostic Test Group, LLC in Boca Raton, FL, and is a sales, marketing and branding company focused on the sale and distribution of its own Clarity brand of rapid and diagnostic tests, molecular tests, and diagnostic equipment utilized in physicians’ offices, clinics, labs, urgent care centers and hospitals. DTG offers one of the largest lines of diagnostic tests in the industry supported by its own national sales force combined with in-house 24-hour customer service and tech support. Clarity products are available at most of the recognized national distributors. The ForeCYTE Breast Health System will form the cornerstone of its newly created division, Clarity Women’s Health.
About Atossa Genetics, Inc.
Atossa Genetics, Inc., The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
Make sure to visit Clarity Women´s Health during this year´s Pri-Med South Annual Conference at booth 402.
Advertising & Marketing Limited
(for Clarity Women´s Health) 954-465-2099 renaemills@admarkjamaica(dot)com
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10414833.htm